# Platinum agents

Source: https://onco.cc/technologies/platinum/  
OnCo record `platinum` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Platinum agents such as cisplatin and carboplatin work by crosslinking DNA. They are curative in testicular cancer and central to lung, ovarian, bladder, head and neck, and TNBC treatment.

## Summary

Platinum agents such as cisplatin and carboplatin form intrastrand DNA crosslinks that trigger apoptosis; the damage is repaired by nucleotide excision and homologous recombination, so tumours with defective homologous recombination are particularly sensitive. They are curative in testicular cancer and central to lung, ovarian, bladder, head and neck, and TNBC treatment. Carboplatin added to neoadjuvant TNBC chemotherapy increases pathologic complete response (BrighTNess, and KEYNOTE-522 includes it). HRD-positive tumours are particularly sensitive, which links platinum response to BRCA biology. Nephrotoxicity, ototoxicity, and neurotoxicity are the main costs, and resistance eventually develops in most metastatic settings. The simple version is that platinum drugs glue DNA strands together so cancer cells cannot copy them.

## Fields

- Kind: Technology
- Status: standard-of-care
- Last checked: 2026-09-04
- Principle: Intrastrand DNA crosslinks trigger apoptosis; repaired by nucleotide excision and homologous recombination.
- Strengths: Broad activity; Synergy with HRD
- Limitations: Nephro-, oto-, neurotoxicity

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Platinum-based_antineoplastic
- Wikipedia: https://en.wikipedia.org/wiki/Platinum-based_antineoplastic

## Connected records

- pairings: [Platinum chemotherapy in HRD tumours](https://onco.cc/pairings/platinum-plus-hrd/)
- cancers: [Basal-like 1 triple-negative breast cancer (BL1)](https://onco.cc/cancers/tnbc-basal-like-1/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [BRCA-associated triple-negative breast cancer](https://onco.cc/cancers/brca-associated-tnbc/), [Cancer of unknown primary (CUP)](https://onco.cc/cancers/cancer-of-unknown-primary/), [Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)](https://onco.cc/cancers/cup-unfavourable/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatoblastoma](https://onco.cc/cancers/hepatoblastoma/), [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)](https://onco.cc/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Testicular germ cell tumours](https://onco.cc/cancers/testicular/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)](https://onco.cc/drugs/folfoxiri/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Platinum + etoposide (EP / CE)](https://onco.cc/drugs/platinum-etoposide/), [Sodium thiosulfate (otoprotectant)](https://onco.cc/drugs/sodium-thiosulfate/)
- trials: [24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC](https://onco.cc/trials/nct07043270/), [5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct04689347/), [A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)](https://onco.cc/trials/nct06966700/), [A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col](https://onco.cc/trials/nct06959693/), [A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course R](https://onco.cc/trials/nct07113275/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07791758/), [A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct07632235/), [A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer](https://onco.cc/trials/nct06885385/), [A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio](https://onco.cc/trials/nct07833202/), [A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC](https://onco.cc/trials/nct05543330/), [A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC](https://onco.cc/trials/nct06177925/), [A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Tr](https://onco.cc/trials/nct06746870/), [A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer](https://onco.cc/trials/nct07283705/), [A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.](https://onco.cc/trials/nct07679399/), [A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P](https://onco.cc/trials/nct07743190/), [A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab](https://onco.cc/trials/nct07318883/), [A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients](https://onco.cc/trials/nct06335355/), [A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions](https://onco.cc/trials/nct04914598/), [A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06919510/), [A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant T](https://onco.cc/trials/nct07239466/), [A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced](https://onco.cc/trials/nct03168880/), [A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer](https://onco.cc/trials/nct07562490/), [A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05654454/), [A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance](https://onco.cc/trials/nct06822543/), [A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs](https://onco.cc/trials/nct06423170/), [A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.](https://onco.cc/trials/nct06654947/), [A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme](https://onco.cc/trials/nct07229846/), [A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line](https://onco.cc/trials/nct07739199/), [A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm](https://onco.cc/trials/nct07802821/), [A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small](https://onco.cc/trials/nct07005128/), [A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f](https://onco.cc/trials/nct07739186/), [A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat](https://onco.cc/trials/nct07822542/), [A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip](https://onco.cc/trials/nct06793215/), [A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers](https://onco.cc/trials/nct05893888/), [A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer](https://onco.cc/trials/nct05990127/), [A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer](https://onco.cc/trials/nct07276399/), [A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea](https://onco.cc/trials/nct06891833/), [A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)](https://onco.cc/trials/nct05849480/), [A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions](https://onco.cc/trials/nct04538664/), [A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer](https://onco.cc/trials/nct02151084/), [A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)](https://onco.cc/trials/nct07108270/), [A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer](https://onco.cc/trials/nct06317311/), [A Study of DS-3939a in Participants With Solid Tumors](https://onco.cc/trials/nct07739966/), [A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.](https://onco.cc/trials/nct07559929/), [A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-](https://onco.cc/trials/nct06362252/), [A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma](https://onco.cc/trials/nct05456256/), [A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer](https://onco.cc/trials/nct07737600/), [A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation](https://onco.cc/trials/nct07814417/), [A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct02711553/), [A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No](https://onco.cc/trials/nct07256509/), [A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC](https://onco.cc/trials/nct06672068/), [A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.](https://onco.cc/trials/nct07258979/), [A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther](https://onco.cc/trials/nct07796100/), [A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo](https://onco.cc/trials/nct06890338/), [A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan](https://onco.cc/trials/nct07756645/), [A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://onco.cc/trials/nct06022861/), [A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors](https://onco.cc/trials/nct07498725/), [A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer](https://onco.cc/trials/nct02632305/), [A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC](https://onco.cc/trials/nct04316364/), [A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer](https://onco.cc/trials/nct07196774/), [A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07393542/), [ABC-02](https://onco.cc/trials/abc-02/), [ABC-06](https://onco.cc/trials/abc-06/), [ABC-07](https://onco.cc/trials/abc-07/), [Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer](https://onco.cc/trials/nct07441369/), [ACTICCA-1](https://onco.cc/trials/acticca-1/), [Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy](https://onco.cc/trials/nct06268327/), [Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07392541/), [Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer](https://onco.cc/trials/nct05179889/), [Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)](https://onco.cc/trials/nct05427669/), [Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer](https://onco.cc/trials/nct02455141/), [AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06591520/), [AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer](https://onco.cc/trials/nct07767994/), [Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer](https://onco.cc/trials/nct07828756/), [Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma](https://onco.cc/trials/nct07780838/), [Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07569679/), [An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct04443543/), [ANITA (Adjuvant Navelbine International Trialist Association)](https://onco.cc/trials/anita/), [Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment](https://onco.cc/trials/nct06662877/), [Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P](https://onco.cc/trials/nct07686796/), [Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas](https://onco.cc/trials/nct05841472/), [Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）](https://onco.cc/trials/nct05794750/), [Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).](https://onco.cc/trials/nct06663098/), [Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy](https://onco.cc/trials/nct03977194/), [AURA3](https://onco.cc/trials/aura3/), [Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel](https://onco.cc/trials/nct06483555/), [Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial](https://onco.cc/trials/nct07610525/), [Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06572813/), [BrighTNess](https://onco.cc/trials/brightness/), [BROCADE3](https://onco.cc/trials/brocade3/), [CALGB 40603 (Alliance)](https://onco.cc/trials/calgb-40603/), [Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct07107217/), [Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct05451290/), [Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07281768/), [CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer](https://onco.cc/trials/nct06881537/), [CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD](https://onco.cc/trials/nct05699746/), [CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C](https://onco.cc/trials/nct07383285/), [CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06281405/), [Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)](https://onco.cc/trials/nct04296175/), [CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC](https://onco.cc/trials/nct06652412/), [CheckMate 026](https://onco.cc/trials/checkmate-026/), [CheckMate 9LA](https://onco.cc/trials/checkmate-9la/), [Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer](https://onco.cc/trials/nct06280508/), [Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial](https://onco.cc/trials/nct06096844/), [Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct07570849/), [CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II](https://onco.cc/trials/nct04120701/), [Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery](https://onco.cc/trials/nct04068103/), [Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06896890/), [CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence](https://onco.cc/trials/nct06037980/), [Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency](https://onco.cc/trials/nct06095141/), [Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer](https://onco.cc/trials/nct07522151/), [Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer](https://onco.cc/trials/nct07827053/), [COG ACNS0332](https://onco.cc/trials/acns0332/), [Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07151872/), [Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct05171660/), [Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07580339/), [ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations](https://onco.cc/trials/combomatch-binimetinib-folfox/), [Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct06632327/), [Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer](https://onco.cc/trials/nct01993810/), [CONKO-003 (OFF)](https://onco.cc/trials/conko-003/), [Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)](https://onco.cc/trials/nct06502080/), [Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07389265/), [Cosiporfin Sodium for Injection Photodynamic Therapy](https://onco.cc/trials/nct07398339/), [CROSS](https://onco.cc/trials/cross/), [Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma](https://onco.cc/trials/nct04339218/), [CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)](https://onco.cc/trials/nct06242418/), [CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers](https://onco.cc/trials/nct06548412/), [Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study](https://onco.cc/trials/nct05067530/), [DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment](https://onco.cc/trials/nct07472517/), [DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy](https://onco.cc/trials/nct07544654/), [DEBATE](https://onco.cc/trials/debate/), [Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer](https://onco.cc/trials/nct02488967/), [Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer](https://onco.cc/trials/nct04137107/), [Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)](https://onco.cc/trials/nct05451043/), [Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer](https://onco.cc/trials/nct05640791/), [EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer](https://onco.cc/trials/ea2197-ivonescimab/), [ECOG-ACRIN EA1131](https://onco.cc/trials/ea1131/), [Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer](https://onco.cc/trials/nct06959082/), [Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com](https://onco.cc/trials/nct04762459/), [Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate](https://onco.cc/trials/nct06282445/), [Efficacy and Safety of CRT, Durvalumab and Surgery for SST](https://onco.cc/trials/nct04465968/), [Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C](https://onco.cc/trials/nct06698965/), [Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM](https://onco.cc/trials/nct07728019/), [Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer](https://onco.cc/trials/nct07638501/), [Efficacy of Hyperthermic Intraperitoneal Chemotherapy](https://onco.cc/trials/nct04861558/), [Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer](https://onco.cc/trials/nct06783491/), [Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer](https://onco.cc/trials/nct05364489/), [Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07003815/), [EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer](https://onco.cc/trials/eortc-1607-pembro-cisgem/), [EORTC 40983](https://onco.cc/trials/eortc-40983/), [Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL](https://onco.cc/trials/nct06806033/), [EXTREME](https://onco.cc/trials/extreme/), [Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.](https://onco.cc/trials/nct05760378/), [First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)](https://onco.cc/trials/nct05749900/), [FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat](https://onco.cc/trials/nct05727163/), [FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery](https://onco.cc/trials/nct06780787/), [FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)](https://onco.cc/trials/nct07621497/), [FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.](https://onco.cc/trials/nct06733038/), [FOxTROT](https://onco.cc/trials/foxtrot/), [Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer](https://onco.cc/trials/nct06441565/), [Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA](https://onco.cc/trials/nct05334277/), [Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07710885/), [GAIN (AIO/CALGP/ACO)](https://onco.cc/trials/gain-igbc/), [Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer](https://onco.cc/trials/nct06591650/), [Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies](https://onco.cc/trials/nct07599995/), [Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct06423326/), [Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)](https://onco.cc/trials/gap-phase2-mdacc/), [Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)](https://onco.cc/trials/nct07433673/), [GeparDouze / NSABP B-59](https://onco.cc/trials/gepardouze/), [GeparSixto](https://onco.cc/trials/geparsixto/), [GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab](https://onco.cc/trials/nct04652076/), [HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer](https://onco.cc/trials/nct06709885/), [Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma](https://onco.cc/trials/nct03364530/), [Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases](https://onco.cc/trials/nct07570914/), [High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct06492759/), [Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis](https://onco.cc/trials/nct04858009/), [Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)](https://onco.cc/trials/nct07183865/), [Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct06928584/), [IALT (International Adjuvant Lung Cancer Trial)](https://onco.cc/trials/ialt/), [IDEA collaboration](https://onco.cc/trials/idea-collaboration/), [Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients](https://onco.cc/trials/nct04159818/), [IMpower110](https://onco.cc/trials/impower110/), [IMpower150](https://onco.cc/trials/impower150/), [Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer](https://onco.cc/trials/nct05914389/), [Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy](https://onco.cc/trials/turrisi-intergroup-0096/), [Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer](https://onco.cc/trials/nct07263360/), [Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis](https://onco.cc/trials/nct07007728/), [Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07238283/), [Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07074353/), [Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC](https://onco.cc/trials/nct07405190/), [JBR.10 (NCIC CTG)](https://onco.cc/trials/jbr-10/), [JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara](https://onco.cc/trials/nct06380348/), [JS212 Combination Therapies in Metastatic Colorectal Cancer](https://onco.cc/trials/nct07503756/), [KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer](https://onco.cc/trials/nct07622017/), [LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis](https://onco.cc/trials/lace-pooled-analysis/), [Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC](https://onco.cc/trials/nct07150949/), [Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy](https://onco.cc/trials/nct07561060/), [LUX-Lung 3](https://onco.cc/trials/lux-lung-3/), [MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma](https://onco.cc/trials/nct06097728/), [mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients](https://onco.cc/trials/nct04084496/), [mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line](https://onco.cc/trials/nct07062536/), [mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC](https://onco.cc/trials/nct06791512/), [mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07817888/), [mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer](https://onco.cc/trials/nct06890624/), [MicroRNA Profiles in Triple Negative Breast Cancer](https://onco.cc/trials/nct04771871/), [Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov](https://onco.cc/trials/nct05456685/), [Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05228431/), [Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer](https://onco.cc/trials/nct05462496/), [MOSAIC](https://onco.cc/trials/mosaic/), [MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma](https://onco.cc/trials/nct07036380/), [Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers](https://onco.cc/trials/nct04910386/), [Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct04159142/), [Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer](https://onco.cc/trials/nct04138719/), [NAPOLI 3](https://onco.cc/trials/napoli-3/), [Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer](https://onco.cc/trials/nct01057069/), [Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC](https://onco.cc/trials/nct07743632/), [Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer](https://onco.cc/trials/nct06790212/), [Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer](https://onco.cc/trials/nct07132008/), [Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07528209/), [Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05479240/), [Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer](https://onco.cc/trials/nct06368141/), [Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC](https://onco.cc/trials/nct07365592/), [Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer](https://onco.cc/trials/nct06205485/), [Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC](https://onco.cc/trials/nct07016399/), [Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients](https://onco.cc/trials/nct06812728/), [Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer](https://onco.cc/trials/nct05132504/), [Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk](https://onco.cc/trials/nct07472868/), [Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer](https://onco.cc/trials/nct05201430/), [Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06443671/), [Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti](https://onco.cc/trials/nct07549906/), [Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)](https://onco.cc/trials/nct07381400/), [Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer](https://onco.cc/trials/nct06407310/), [Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients](https://onco.cc/trials/nct06280495/), [Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)](https://onco.cc/trials/nct07283692/), [Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06718543/), [Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.](https://onco.cc/trials/nct07394387/), [Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）](https://onco.cc/trials/nct05429463/), [Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma](https://onco.cc/trials/nct06903273/), [Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct05571644/), [Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)](https://onco.cc/trials/nct06384560/), [NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients](https://onco.cc/trials/nct06845319/), [NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)](https://onco.cc/trials/nct05529940/), [NeoPACT](https://onco.cc/trials/neopact/), [Neotorch](https://onco.cc/trials/neotorch/), [NeoTRIP (NeoTRIPaPDL1)](https://onco.cc/trials/neotrip/), [New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy](https://onco.cc/trials/nct04564157/), [Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer](https://onco.cc/trials/nct06389760/), [Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer](https://onco.cc/trials/nct06204094/), [Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer](https://onco.cc/trials/nct06507371/), [Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer](https://onco.cc/trials/nct05972655/), [NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC](https://onco.cc/trials/nct04335669/), [Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer](https://onco.cc/trials/nct05485766/), [Omitting CTV for Primary Tumor in LS-SCLC](https://onco.cc/trials/nct07008716/), [Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)](https://onco.cc/trials/nct06919848/), [Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer](https://onco.cc/trials/nct06736717/), [Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T](https://onco.cc/trials/nct06318897/), [OPT-IN (EA2197)](https://onco.cc/trials/opt-in/), [Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07040098/), [Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot](https://onco.cc/trials/nct07001618/), [ORATOR](https://onco.cc/trials/orator/), [Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct04938583/), [Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer](https://onco.cc/trials/nct05605535/), [Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer](https://onco.cc/trials/nct05969847/), [Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study](https://onco.cc/trials/nct06390982/), [Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers](https://onco.cc/trials/nct04410796/), [Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations](https://onco.cc/trials/nct04695925/), [PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer](https://onco.cc/trials/nct05236972/), [Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN](https://onco.cc/trials/nct06910072/), [PARTNER](https://onco.cc/trials/partner/), [Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC](https://onco.cc/trials/nct04153734/), [Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06230471/), [Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287](https://onco.cc/trials/nct06422143/), [Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A](https://onco.cc/trials/nct04846634/), [Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)](https://onco.cc/trials/nct06960577/), [Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers](https://onco.cc/trials/nct06001658/), [Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More](https://onco.cc/trials/nct06293625/), [Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC](https://onco.cc/trials/nct04585490/), [Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test](https://onco.cc/trials/nct07340567/), [PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC](https://onco.cc/trials/nct06245889/), [Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon](https://onco.cc/trials/nct07413601/), [Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer](https://onco.cc/trials/nct06467357/), [Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation](https://onco.cc/trials/nct06110572/), [Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)](https://onco.cc/trials/nct07243938/), [Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer](https://onco.cc/trials/nct06852287/), [Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06708858/), [Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC](https://onco.cc/trials/nct05239650/), [Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC](https://onco.cc/trials/nct07603791/), [Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07154316/), [Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets](https://onco.cc/trials/nct07234877/), [Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer](https://onco.cc/trials/nct07017673/), [Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous](https://onco.cc/trials/nct07360132/), [Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No](https://onco.cc/trials/nct07383116/), [Phase III Study of AK112 for NSCLC Patients](https://onco.cc/trials/nct06396065/), [Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC](https://onco.cc/trials/nct07754123/), [Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act](https://onco.cc/trials/nct07829549/), [Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations](https://onco.cc/trials/nct05687266/), [PhII ICb With/Without Erbitux in MBC Pts](https://onco.cc/trials/nct00248287/), [POLCAGB](https://onco.cc/trials/polcagb/), [Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer](https://onco.cc/trials/nct06802757/), [Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)](https://onco.cc/trials/nct05008809/), [Pre-Operative Treatment in REseCTable COlon CanceR](https://onco.cc/trials/nct06899477/), [Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study](https://onco.cc/trials/nct07729917/), [Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut](https://onco.cc/trials/nct06784791/), [Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct06751394/), [Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct04495088/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/), [PRODIGE 4 / ACCORD 11](https://onco.cc/trials/prodige-4-accord-11/), [PROFILE 1014](https://onco.cc/trials/profile-1014/), [Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC](https://onco.cc/trials/nct03478488/), [Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC](https://onco.cc/trials/nct07103447/), [Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC](https://onco.cc/trials/nct06745882/), [Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Co](https://onco.cc/trials/nct03671252/), [Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases](https://onco.cc/trials/nct03965234/), [PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM](https://onco.cc/trials/nct06788171/), [QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors](https://onco.cc/trials/nct06892925/), [QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer](https://onco.cc/trials/nct07025239/), [QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer](https://onco.cc/trials/nct06404736/), [QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer](https://onco.cc/trials/nct07156682/), [QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer](https://onco.cc/trials/nct07733115/), [QLS5132 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07453394/), [Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）](https://onco.cc/trials/nct06949111/), [Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer](https://onco.cc/trials/nct07562711/), [Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer](https://onco.cc/trials/nct07562503/), [RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer](https://onco.cc/trials/nct05966194/), [RUGB](https://onco.cc/trials/rugb/), [Sacituzumab Govitecan in Primary HER2-negative Breast Cancer](https://onco.cc/trials/nct04595565/), [Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A](https://onco.cc/trials/nct06305754/), [Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer](https://onco.cc/trials/nct06712355/), [Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer](https://onco.cc/trials/nct06274879/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.](https://onco.cc/trials/nct06835179/), [SCOT](https://onco.cc/trials/scot/), [SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07551479/), [SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer](https://onco.cc/trials/nct07837362/), [SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05576480/), [SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases](https://onco.cc/trials/nct06787183/), [Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07025174/), [Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05731726/), [Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07819604/), [Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)](https://onco.cc/trials/nct06455124/), [Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer](https://onco.cc/trials/nct06462053/), [Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for](https://onco.cc/trials/nct06872606/), [Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct06802666/), [Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct07469306/), [SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer](https://onco.cc/trials/nct07297030/), [Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07831993/), [Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM](https://onco.cc/trials/nct05902169/), [Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer](https://onco.cc/trials/nct05501665/), [SQUIRE](https://onco.cc/trials/squire/), [Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct04722978/), [Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC](https://onco.cc/trials/nct06165900/), [Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04665856/), [Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations](https://onco.cc/trials/nct07598318/), [Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07129993/), [Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)](https://onco.cc/trials/nct06048133/), [Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer](https://onco.cc/trials/nct05403385/), [Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C](https://onco.cc/trials/nct07680790/), [Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer](https://onco.cc/trials/nct06783140/), [Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)](https://onco.cc/trials/nct06797635/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta](https://onco.cc/trials/nct07702032/), [Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.](https://onco.cc/trials/nct07638852/), [Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can](https://onco.cc/trials/nct06704620/), [Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma](https://onco.cc/trials/nct03967977/), [Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.](https://onco.cc/trials/nct06431633/), [Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [](https://onco.cc/trials/nct02486718/), [Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer](https://onco.cc/trials/nct04725994/), [Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax](https://onco.cc/trials/nct01081951/), [Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced C](https://onco.cc/trials/nct06888843/), [Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC](https://onco.cc/trials/nct07833241/), [Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct07469956/), [SWOG S1815](https://onco.cc/trials/swog-s1815/), [SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07662811/), [SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST](https://onco.cc/trials/nct07633873/), [TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature](https://onco.cc/trials/nct02641847/), [Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC](https://onco.cc/trials/nct07786428/), [Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA](https://onco.cc/trials/nct04183712/), [Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers](https://onco.cc/trials/nct07437287/), [Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun](https://onco.cc/trials/nct03811002/), [Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch](https://onco.cc/trials/nct04267848/), [Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage](https://onco.cc/trials/nct05610163/), [Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti](https://onco.cc/trials/nct04092283/), [Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct03606967/), [Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study](https://onco.cc/trials/nct02997228/), [Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05624996/), [Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer](https://onco.cc/trials/nct03793179/), [The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer](https://onco.cc/trials/nct05628038/), [The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer](https://onco.cc/trials/nct05555888/), [The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra](https://onco.cc/trials/nct06266832/), [The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi](https://onco.cc/trials/nct07204574/), [The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06115499/), [The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer](https://onco.cc/trials/nct05422690/), [The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a](https://onco.cc/trials/nct06946901/), [The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors](https://onco.cc/trials/nct07109167/), [The Sagittarius Trial](https://onco.cc/trials/nct06490536/), [TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC](https://onco.cc/trials/nct07074106/), [TNT (Triple Negative Trial)](https://onco.cc/trials/tnt/), [TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05646511/), [to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu](https://onco.cc/trials/nct04301739/), [TOSCA](https://onco.cc/trials/tosca/), [Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Canc](https://onco.cc/trials/nct07810114/), [Total Neoadjuvant Therapy in Rectal Cancer](https://onco.cc/trials/nct06162650/), [Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer](https://onco.cc/trials/nct07662031/), [TRAIN-2](https://onco.cc/trials/train-2/), [TRAP-BTC](https://onco.cc/trials/trap-btc/), [Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT](https://onco.cc/trials/nct04137653/), [Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer](https://onco.cc/trials/nct06291064/), [TRIBE](https://onco.cc/trials/tribe/), [Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer](https://onco.cc/trials/nct07146646/), [Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer](https://onco.cc/trials/nct07267078/), [Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer](https://onco.cc/trials/nct07503639/), [Using ctDNA to Determine Therapies for Lung Cancer](https://onco.cc/trials/nct04966663/), [Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients](https://onco.cc/trials/nct05821556/), [Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct04094688/), [XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)](https://onco.cc/trials/nct07381777/), [YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct05767892/), [Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07229339/), [Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers](https://onco.cc/trials/nct07723534/)
- terms: [Chemotherapy](https://onco.cc/terms/chemotherapy-term/), [Homologous recombination deficiency (HRD) in breast cancer](https://onco.cc/terms/hrd-in-breast-cancer/), [Platinum-sensitive / platinum-resistant](https://onco.cc/terms/platinum-sensitivity/)
- key papers: [ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer](https://onco.cc/key-papers/paper-adriatic-nejm-2024/), [CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma](https://onco.cc/key-papers/paper-checkmate-649-lancet-2021/), [Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer](https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/), [Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies](https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/), [Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)](https://onco.cc/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/), [KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer](https://onco.cc/key-papers/paper-keynote-048-lancet-2019/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)](https://onco.cc/key-papers/paper-keynote-a18-os-lancet-2024/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)](https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/), [Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial](https://onco.cc/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/), [Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline](https://onco.cc/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/), [NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer](https://onco.cc/key-papers/paper-napoli-3-lancet-2023/), [NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-niagara-nejm-2024/), [PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer](https://onco.cc/key-papers/paper-pacific-nejm-2017/), [Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto](https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/), [Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer](https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/), [Whole genomes redefine the mutational landscape of pancreatic cancer](https://onco.cc/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/)
- roadmaps: [TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line](https://onco.cc/roadmaps/tnbc-history/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- people: [Aimery de Gramont](https://onco.cc/people/aimery-de-gramont/), [Andrew Tutt](https://onco.cc/people/andrew-tutt/), [Jan B. Vermorken](https://onco.cc/people/jan-vermorken/), [Jean Abraham](https://onco.cc/people/jean-abraham/), [Xichun Hu](https://onco.cc/people/hu-xichun/)
- pathways: [DNA damage response & homologous recombination](https://onco.cc/pathways/ddr/), [DNA replication & origin licensing](https://onco.cc/pathways/dna-replication-licensing/), [Double-strand break repair: HR versus end joining](https://onco.cc/pathways/homologous-recombination-repair/)
- ideas: [A non-profit manufacturer for generic cancer drugs in chronic shortage](https://onco.cc/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/), [A non-profit manufacturer for shortage-prone generic chemotherapy](https://onco.cc/ideas/idea-cost-nonprofit-generic-oncology/), [A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression](https://onco.cc/ideas/idea-moon-neuropathy-prevention-programme/), [A strategic reserve of essential generic cancer drugs to end recurring shortages](https://onco.cc/ideas/idea-reg-generic-chemo-strategic-reserve/), [Protect hearing from cisplatin in adults as we now do in children](https://onco.cc/ideas/idea-moon-hearing-protection-cisplatin/), [Public-option manufacturing for essential generic cancer drugs in shortage](https://onco.cc/ideas/idea-fund-public-option-generic-oncology/)
- technologies: [Generic oncology drug supply and shortage mitigation](https://onco.cc/technologies/generic-drug-shortage-response/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/)
- institutions: [Indiana University Melvin and Bren Simon Comprehensive Cancer Center](https://onco.cc/institutions/iu-simon/)

---
JSON: https://onco.cc/api/v1/entities/platinum.json